Avalyn Pharma (AVLN) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nuvation Bio is the larger company by market cap ($1.34 billion vs $1.26 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | NUVB |
|---|---|---|
| Share price | $28.40 | $3.80 |
| Market cap | $1.26B | $1.34B |
| 1-day change | -1.05% | -0.26% |
| YTD return | — | -57.59% |
| 1-year return | — | -45.64% |
| 5-year return | — | -53.49% |
| EPS (TTM) | $-3.96 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.90M |
| Revenue growth (YoY) | — | +698.96% |
| Net income (latest FY) | — | $-204.63M |
| Operating margin | — | -338.72% |
| Net margin | — | -325.31% |
| 52-week high | $40.17 | $9.75 |
| 52-week low | $22.24 | $3.71 |
| Distance from 52-week high | -29.30% | -61.03% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +114.79% | +227.63% |
| Average volume | 352.95K | 5.24M |
| Shares outstanding | 44.52M | 352.02M |
| Employees | 56 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees
AVLN vs NUVB FAQ
Which is bigger, Avalyn Pharma or Nuvation Bio?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.34B compared with $1.26B for Avalyn Pharma (AVLN).
Are Avalyn Pharma and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.